Repare Therapeutics describes new PKMYT1 inhibitors for cancer
Dec. 13, 2023
Repare Therapeutics Inc. has identified membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.